

CASE AND RESEARCH LETTER

Mucous Membrane Pemphigoid After SARS-CoV-2 Vaccine



Penfigoide de mucosas tras vacunación contra SARS-CoV-2

To the Editor,

New onset of autoimmune blistering skin diseases may be impacted by several factors, such as drugs, viruses, or vaccines. Isolated cases may be induced by SARS-CoV-2 vaccination.¹ We report an unusual case of mucous membrane pemphigoid (MMP) triggered by SARS-CoV-2 vaccine.

A 75-year-old-woman was evaluated for painful oral mucosal lesions. No personal dermatological diseases were reported. The patient came with a 12-month history of lesions she noticed 1 week after having received the 2nd dose of the Pfizer SARS-CoV-2 vaccine. Previous treatment with topical corticosteroids had been unsuccessful. Physical examination revealed the presence of erosive and erythematous plaques on the upper and lower gingivae (Fig. 1a, b). Neither the skin nor the other mucosal surfaces were affected. The oral mucosal biopsy performed revealed the presence of subepidermal detachment and inflammatory cells including eosinophils (Fig. 1c, d). Direct immunofluorescence showed linear depositions of IgG and C3 along the epidermal basement membrane zone (Fig. 1e, f). Moreover, using the salt-split procedure (IIF-SS) linear IgG deposits (1:40) were seen on the epidermal side (Fig. 2a, b). An ELISA test performed on the patient's serum detected a high level of anti-BP-180 antibodies (116 U/mL; normal < 20 U/mL). By immunoblotting assay, IgG against the C-terminal and LAD-1 domains of BP180 were found (Fig. 2c, d). Our patient was diagnosed with anti-BP180-type MMP, probably induced by the SARS-CoV-2 vaccine. Dapsone 50 mg/12 h and topical clobetasol propionate were initiated, leading to lesion improvement until complete remission was achieved 4 months later.

Globally, several cases of autoimmune disorders, including autoimmune bullous diseases (AIBDs), have reportedly been developed after SARS-CoV-2 vaccination.² Currently, only 6% of patients with AIBDs after SARS-CoV-2 vaccines developed de novo AIBDs. The reported AIBDs after the

administration of the SARS-CoV-2 vaccine are bullous pemphigoid, linear IgA disease, pemphigus vulgaris, MMP and pemphigus foliaceus.¹ In most cases, vesicular and bullous eruptions flared up after the administration of the 1st and/or 2nd doses.

The development of autoimmune bullous oral lesions after SARS-CoV-2 vaccination has been infrequently reported in literature and usually in association with skin lesions. There is a slight prevalence for women (69%), and the mean time of onset following vaccination is 9.4 days. The BNT162b2 BioNTech vaccine (Pfizer) tends to trigger autoimmune oral lesions more frequently.³ Only 2 cases of MMP after SARS-CoV-2 vaccination have been reported^{4,5} (Table 1). All these patients provide interesting information. First, MMP after SARS-CoV-2 vaccination occurred mainly in women, same as conventional MMP. The 3 patients developed exclusively oral mucosal lesions and 2 patients exhibited IgG autoantibodies vs BP180 detected by ELISA. In addition, our case developed IgG autoantibodies vs LAD-1 and the C-terminal domains of BP180 as shown by immunoblotting assays. In our case, IIF-SS showed IgG reactivity with the epidermal side. Finally, all 3 MMP cases induced by SARS-CoV-2 vaccine had an excellent prognosis after treatment, probably due to the self-limited effect associated with the vaccine. All these findings indicate that SARS-CoV-2 vaccination could trigger MMP.

A cause–effect relationship between SARS-CoV-2 vaccine and autoimmunity has not been completely established to this date. Several hypotheses have been postulated as an explanation for the new onset or flare-ups of AIBD following SARS-CoV-2 vaccination. These theories include molecular mimicry between the virus and human proteins, bystander activation, anti-idiotypic networks, and epitope spreading.² Moreover, vaccine adjuvants may enhance an immune response. Of note, SARS-CoV-2 vaccines generate spike proteins, which may bind to the angiotensin-converting enzyme-2 receptors on keratinocytes, thus leading to the recruitment of CD4+ lymphocytes. Nevertheless, a recent meta-analysis of autoimmune skin disorders after SARS-CoV-2 vaccination shows that they are not associated with a higher risk than other triggering factors,⁶ meaning that it should be recommended in patients who need protection vs SARS-CoV-2 infection.




Figure 1 (a, b) Erosive and erythematous plaques with a diameter of up to 1 cm affecting the marginal, interdental, and attached gingiva. (c, d) Representative histologic image from the biopsy showing a subepidermal blister and multiple inflammatory cells including eosinophils (hematoxylin and eosin, $\times 100$ (c) and $\times 200$ (d)). (e, f) IFD test showing (e) linear deposition of IgG ($\times 200$) and (f) C3 along the dermoepidermal junction ($\times 200$).

Table 1 Cases reported of mucous membrane pemphigoid after COVID vaccine.

Authors	Gender/age (years)	Clinical signs	Timing	Histology	Autoantibodies	Type of vaccine	Treatment/ outcome	Comorbidities/ treatment
Rungraungrayabku D et al. ⁴	Female/74	Erythema, erosions, blisters, gingival mucosa	2 weeks after 1st dose of vaccine	Subepithelial blister DIF: linear IgG and C3 deposits IIF: not shown	Not shown	BNT162b2 vaccine BioNTech (Pfizer)	Doxycycline, topical cortosteroids Improvement	Not relevant
Calabria E et al. ⁵	Female/72	Erythema, erosions, blisters, upper and lower gingivae extended bilaterally to the vestibular fornix and right buccal mucosa	9 days after 3rd dose of vaccine	Subepithelial detachment DIF: linear IgG/IgA deposits, granular C3 deposits	ELISA: IgG vs BP180	BNT162b2 vaccine BioNTech (Pfizer)	Antibiotics, topical and systemic corticosteroids Complete response	Breast cancer Aromatase inhibitor Denosumab
Our case	Female/75	Erythema, upper and lower gingivae	7 days after 2nd dose of vaccine	Subepithelial detachment DIF: linear IgG and C3 deposits IIF/salt split: IgG reacted with epidermal side of the split	ELISA: IgG vs BP180 IB: IgG BP180 C-terminal and LAD-1 domains	BNT162b2 vaccine BioNTech (Pfizer)	Topical and systemic corticosteroids Dapsone Gradual improvement	Not relevant




Figure 2 (a, b) Indirect immunofluorescence images. (a) Patient's IgG react on basement membrane zone, 1:10 dilution ($\times 200$). (b) Patient's IgG react on epidermal side of the section, 1:40 dilution ($\times 200$). (c, d) Immunoblotting assay showing IgG vs the C-terminal and LAD-1 domains (HaCaT) of BP180. Results tested negative for epidermal (desmoglein 1 and 3) and dermal extracts, BP180 NC16a, and Laminin-332.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Kasperkiewicz M, Woodley DT. COVID-19 and autoimmune bullous diseases: lessons learned. *Autoimmun Rev*. 2023;22:103286, <http://dx.doi.org/10.1016/j.autrev.2023.103286>.
- Kasperkiewicz M, Woodley DT. Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19. *J Eur Acad Dermatol Venerol*. 2022;36:e498–500, <http://dx.doi.org/10.1111/jdv.18030>.
- Di Spirito F, Amato A, Di Palo MP, Contaldo M, D'Ambrosio F, Lo Giudice R, et al. Oral lesions following anti-SARS-CoV-2 vaccination: a systematic review. *Int J Environ Res Public Health*. 2022;19:10228, <http://dx.doi.org/10.3390/ijerph191610228>.
- Rungraungrayabkul D, Rattanasiriphan N, Juengsomjit R. Mucous membrane pemphigoid following the administration of COVID-19 vaccine. *Head Neck Path*. 2023;28:1–2, <http://dx.doi.org/10.1007/s12105-023-01539-9>.
- Calabria E, Antenelli A, Lavecchia A, Giudice A. Oral mucous membrane pemphigoid after SARS-CoV-2 vaccination. *Oral Dis*. 2022;1–2, <http://dx.doi.org/10.1111/odi.14468>.
- Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS-CoV-2 vaccination – a meta-analysis. *J Dtsch Dermatol Ges*. 2023;21:853–61, <http://dx.doi.org/10.1111/ddg.15114>.

I. Oteiza-Rius^{a,*}, T. Hashimoto^b, N. Ishii^c, A. España^a

^a *Dermatology Department of Clínica Universidad de Navarra, Pamplona, Spain*

^b *Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan*

^c *Kurume University School of Medicine, Kurume, Japan*

* Corresponding author.

E-mail address: ioteiza@unav.es (I. Oteiza-Rius).